Published in Lancet on April 11, 2009
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
Vitamin D levels and response to biphosphonates in postmenopausal women receiving glucocorticoid therapy. Osteoporos Int (2014) 5.05
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int (2010) 1.83
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res (2016) 1.50
The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol (2010) 1.44
A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol (2013) 1.40
UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos (2017) 1.40
Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study. BMC Musculoskelet Disord (2011) 1.37
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 1.36
Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am (2012) 1.32
Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol (2010) 1.16
Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol (2011) 1.04
Aging and bone loss: new insights for the clinician. Ther Adv Musculoskelet Dis (2012) 1.02
Raman spectroscopy detects deterioration in biomechanical properties of bone in a glucocorticoid-treated mouse model of rheumatoid arthritis. J Biomed Opt (2011) 1.02
A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res Ther (2009) 0.94
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf (2010) 0.92
Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporos Int (2012) 0.91
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract (2011) 0.88
Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis (2014) 0.87
Glucocorticoid-induced osteoporosis in rheumatic diseases. Clinics (Sao Paulo) (2010) 0.87
Do bisphosphonates cause femoral insufficiency fractures? J Orthop Traumatol (2012) 0.87
Complications of long-term therapy for ANCA-associated systemic vasculitis. Nat Rev Nephrol (2012) 0.86
Clinical role of bisphosphonate therapy. Int J Womens Health (2012) 0.85
Progress in osteoporosis and fracture prevention: focus on postmenopausal women. Arthritis Res Ther (2009) 0.85
Increase in prophylaxis of glucocorticoid-induced osteoporosis by pharmacist feedback: a randomised controlled trial. Osteoporos Int (2013) 0.84
Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol (2015) 0.83
Recognizing and treating secondary osteoporosis. Nat Rev Rheumatol (2012) 0.82
Glucocorticoid-induced osteoporosis: treatment update and review. Ther Adv Musculoskelet Dis (2009) 0.82
Glucocorticoids and osteocyte autophagy. Bone (2013) 0.82
Glucocorticoid-induced osteoporosis: hope on the HORIZON. Lancet (2009) 0.82
Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. Osteoporos Int (2015) 0.82
Role of zoledronic acid in the prevention and treatment of osteoporosis. Clin Interv Aging (2011) 0.82
Glucocorticoid-induced osteoporosis. RMD Open (2015) 0.82
Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug Des Devel Ther (2010) 0.81
Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions. Ther Adv Musculoskelet Dis (2013) 0.81
Updated recommendations for the diagnosis and management of osteoporosis: a local perspective. Ann Saudi Med (2011) 0.81
Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. Arthritis Res Ther (2010) 0.80
Zoledronic acid-induced hepatotoxicity relieved after subsequent infusions in a Chinese woman with glucocorticoid-induced osteoporosis. Eur J Med Res (2015) 0.80
Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation. J Clin Endocrinol Metab (2012) 0.80
Longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica. Rheumatol Int (2014) 0.79
An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy. Mayo Clin Proc (2010) 0.79
The effect of angiotensin-converting enzyme inhibitor use on bone loss in elderly Chinese. J Bone Miner Metab (2012) 0.79
Glucocorticoid-induced osteoporosis - a disorder of mesenchymal stromal cells? Front Endocrinol (Lausanne) (2011) 0.79
A single dose of zoledronic acid reverses the deleterious effects of glucocorticoids on titanium implant osseointegration. Osteoporos Int (2009) 0.79
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 0.79
Bisphosphonates and glucocorticoid-induced osteoporosis: cons. Endocrine (2015) 0.78
Prevention of glucocorticoid induced bone changes with beta-ecdysone. Bone (2015) 0.78
Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis. Ther Adv Musculoskelet Dis (2010) 0.78
Glucocorticoid-induced osteoporosis: how best to avoid fractures. Ther Adv Chronic Dis (2010) 0.78
Osteoporosis in men: a review. Bone Res (2014) 0.78
Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates. J Bone Miner Metab (2012) 0.78
Lipid metabolism disorders and bone dysfunction--interrelated and mutually regulated (review). Mol Med Rep (2015) 0.77
Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis. Ther Clin Risk Manag (2010) 0.77
Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int (2015) 0.77
Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease. Osteoporos Int (2012) 0.76
Management issues with exogenous steroid therapy. Indian J Endocrinol Metab (2013) 0.76
Treatment of glucocorticoid-induced osteoporsis. Ther Adv Musculoskelet Dis (2009) 0.76
Medical treatment of osteoporotic vertebral fractures. Ther Adv Musculoskelet Dis (2011) 0.76
An overview and management of osteoporosis. Eur J Rheumatol (2016) 0.75
Intravenous zoledronate for osteoporosis: less might be more. Ther Adv Musculoskelet Dis (2016) 0.75
Very high frequency of fragility fractures associated with high-dose glucocorticoids in postmenopausal women: A retrospective study. Bone Rep (2016) 0.75
Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study). Osteoporos Int (2016) 0.75
[A single infusion of zoledronic acid (Zometa) for prevention and treatment of steroid-induced osteoporosis]. Praxis (Bern 1994) (2009) 0.75
Comorbidities: glucocorticoids and osteoporosis: predicting fracture risk. Nat Rev Rheumatol (2010) 0.75
Recent advances in managing osteoporosis. F1000 Med Rep (2009) 0.75
A Case Report of Bisphosphonate-induced Bilateral Osteoporotic Subtrochanteric Fracture Femurii: Review of Literature. J Orthop Case Reports (2017) 0.75
Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis. Patient Prefer Adherence (2010) 0.75
Characteristics of lumbar scoliosis in patients with rheumatoid arthritis. J Orthop Surg Res (2014) 0.75
[Prophylaxis and therapy of the glucocorticoid-induced osteoporosis - a review of recent guidelines]. Wien Klin Wochenschr (2011) 0.75
Surgical trauma and low-dose methylprednisolone modulate the severity of the acute-phase response induced by zoledronic acid infusion. Exp Ther Med (2017) 0.75
Long-term leukopenia in a lung transplanted patient with cystic fibrosis treated with zoledronic acid: a case report. Osteoporos Int (2016) 0.75
Adverse bone effects of medications used to treat non-skeletal disorders. Osteoporos Int (2017) 0.75
Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study. Osteoporos Int (2017) 0.75
Glucocorticoid-induced Osteoporosis. Indian J Endocrinol Metab (2017) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med (2004) 8.86
Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am (2004) 7.59
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis (2012) 4.81
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med (2003) 3.07
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res (2011) 2.53
Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question. Arthritis Care Res (Hoboken) (2013) 2.53
Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet (2011) 2.34
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int (2008) 2.29
A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET. IEEE Trans Med Imaging (2009) 2.22
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res (2010) 2.20
Outcomes from the Patient Perspective Workshop at OMERACT 6. J Rheumatol (2003) 2.20
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum (2009) 2.16
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in a population-based sample: the OPUS Study. J Bone Miner Res (2004) 2.01
Loss of muscle strength, mass (sarcopenia), and quality (specific force) and its relationship with functional limitation and physical disability: the Concord Health and Ageing in Men Project. J Am Geriatr Soc (2010) 1.97
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res (2010) 1.95
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone (2007) 1.94
Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice? J Rheumatol (2006) 1.92
Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol (2007) 1.87
2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine (2012) 1.85
Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet (2013) 1.82
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 1.82
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
Carpal tunnel syndrome and its relationship to occupation: a meta-analysis. Rheumatology (Oxford) (2011) 1.80
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Pain, frailty and comorbidity on older men: the CHAMP study. Pain (2008) 1.79
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res (2012) 1.78
Prediction of hip fracture risk by quantitative ultrasound in more than 7000 Swiss women > or =70 years of age: comparison of three technologically different bone ultrasound devices in the SEMOF study. J Bone Miner Res (2006) 1.78
Atypical antipsychotic medications and risk of falls in residents of aged care facilities. J Am Geriatr Soc (2005) 1.73
Septic knee arthritis after intra-articular hyaluronate injection. Two case reports. Joint Bone Spine (2005) 1.67
Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res (2013) 1.66
Novel genetic variants associated with lumbar disc degeneration in northern Europeans: a meta-analysis of 4600 subjects. Ann Rheum Dis (2012) 1.66
The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum (2007) 1.65
Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Curr Med Res Opin (2012) 1.64
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc (2010) 1.62
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab (2013) 1.60
How fast does the Grim Reaper walk? Receiver operating characteristics curve analysis in healthy men aged 70 and over. BMJ (2011) 1.59
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med J Aust (2002) 1.59
Structural, psychological, and genetic influences on low back and neck pain: a study of adult female twins. Arthritis Rheum (2004) 1.57
Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause (2004) 1.57
Pattern of arterial calcification in patients with systemic lupus erythematosus. J Rheumatol (2009) 1.57
Calcium supplementation: balancing the cardiovascular risks. Maturitas (2011) 1.56
Hypovitaminosis D and parathyroid hormone response in the elderly: effects on bone turnover and mortality. Clin Endocrinol (Oxf) (2007) 1.55
WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet (2012) 1.55
Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am (2012) 1.54
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res (2010) 1.54
2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine (2014) 1.54
Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2009) 1.54
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab (2008) 1.53
Lumbar disc degeneration and genetic factors are the main risk factors for low back pain in women: the UK Twin Spine Study. Ann Rheum Dis (2011) 1.53
Role of circulating endothelial progenitor cells in patients with rheumatoid arthritis with coronary calcification. J Rheumatol (2010) 1.52
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med (2004) 1.51
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Strategies for the prevention of hip fracture. Am J Med (2003) 1.50
A watermarking-based medical image integrity control system and an image moment signature for tampering characterization. IEEE J Biomed Health Inform (2013) 1.49
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. Bone (2008) 1.48
Adaptive nonseparable wavelet transform via lifting and its application to content-based image retrieval. IEEE Trans Image Process (2010) 1.48
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone (2008) 1.44
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab (2007) 1.43
Controlled whole body vibration to decrease fall risk and improve health-related quality of life of nursing home residents. Arch Phys Med Rehabil (2005) 1.42
Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res (2005) 1.42
Hip cortical thickness assessment in postmenopausal women with osteoporosis and strontium ranelate effect on hip geometry. J Clin Densitom (2012) 1.42
Vertebral Fracture Assessment: the 2007 ISCD Official Positions. J Clin Densitom (2008) 1.42
Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). J Clin Endocrinol Metab (2014) 1.41
The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine (2011) 1.41
Male osteoporosis: diagnosis and fracture risk evaluation. Joint Bone Spine (2009) 1.40
Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int (2005) 1.36
Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab (2007) 1.32
Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res (2012) 1.29
Use of a JPEG-2000 Wavelet Compression Scheme for Content-Based Ophtalmologic Retinal Images Retrieval. Conf Proc IEEE Eng Med Biol Soc (2005) 1.28
Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am (2008) 1.27
Retinopathy online challenge: automatic detection of microaneurysms in digital color fundus photographs. IEEE Trans Med Imaging (2009) 1.26
Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage (2004) 1.25